{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:35:34Z","timestamp":1759538134078,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13397-y","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:21:05Z","timestamp":1759490465000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial disparities and trends in anticoagulant use among ambulatory care patients with atrial fibrillation and atrial flutter in the United States from 2007 to 2019"],"prefix":"10.1186","volume":"25","author":[{"given":"Vincent","family":"Kan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McManus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonggyu","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Darling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Alcusky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"9","key":"13397_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042\u20136.","journal-title":"Circulation"},{"issue":"2","key":"13397_CR2","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"2","key":"13397_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/01.STR.0000153002.56324.8c","volume":"36","author":"PS Miller","year":"2005","unstructured":"Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36(2):360\u20136.","journal-title":"Stroke"},{"issue":"10","key":"13397_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"13397_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"13397_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"12","key":"13397_CR7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","volume":"3","author":"UR Essien","year":"2018","unstructured":"Essien UR, Holmes DN, Jackson LR, et al. Association of race\/ethnicity with oral anticoagulant use in patients with atrial fibrillation: findings from the outcomes registry for better informed treatment of atrial fibrillation II. JAMA Cardiol. 2018;3(12):1174\u201382.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"13397_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14234","volume":"4","author":"UR Essien","year":"2021","unstructured":"Essien UR, Kim N, Hausmann LR, et al. Disparities in anticoagulant therapy initiation for incident atrial fibrillation by race\/ethnicity among patients in the veterans health administration system. JAMA Netw Open. 2021;4(7):e2114234-2114234.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"13397_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005600","volume":"12","author":"AS Nathan","year":"2019","unstructured":"Nathan AS, Geng Z, Dayoub EJ, et al. Racial, ethnic, and socioeconomic inequities in the prescription of direct oral anticoagulants in patients with venous thromboembolism in the United States. Circ Cardiovasc Qual Outcomes. 2019;12(4):e005600.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"13397_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","volume":"38","author":"J Zhu","year":"2018","unstructured":"Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010\u20132017. Pharmacotherapy. 2018;38(9):907\u201320.","journal-title":"Pharmacotherapy"},{"issue":"22","key":"13397_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, et al. Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc. 2022;11(22):e026723.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"13397_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.amjcard.2017.05.055","volume":"120","author":"JM Ashburner","year":"2017","unstructured":"Ashburner JM, Singer DE, Lubitz SA, Borowsky LH, Atlas SJ. Changes in use of anticoagulation in patients with atrial fibrillation within a primary care network associated with the introduction of direct oral anticoagulants. Am J Cardiol. 2017;120(5):786\u201391.","journal-title":"Am J Cardiol"},{"issue":"11","key":"13397_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.amjmed.2014.05.013","volume":"127","author":"NR Desai","year":"2014","unstructured":"Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation\u2014quality and cost implications. Am J Med. 2014;127(11):1075\u201382. e1.","journal-title":"Am J Med"},{"issue":"5","key":"13397_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","volume":"5","author":"K Kirley","year":"2012","unstructured":"Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615\u201321.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"16","key":"13397_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2146\/ajhp160756","volume":"74","author":"AA Alalwan","year":"2017","unstructured":"Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health-Syst Pharm. 2017;74(16):1237\u201344.","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"13397_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","volume":"128","author":"GD Barnes","year":"2015","unstructured":"Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300\u20135. e2.","journal-title":"Am J Med"},{"key":"13397_CR17","unstructured":"Hing E, Burt CW. Office-based medical practices: methods and estimates from the national ambulatory medical care survey. Adv Data. 2007;(383):1\u201315."},{"key":"13397_CR18","unstructured":"Hing E, Shimizu IM, Talwalkar A. Nonresponse Bias in Estimates From the 2012 National Ambulatory Medical Care Survey. Vital Health Stat 2. 2016;(171):1\u201342."},{"issue":"1","key":"13397_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010083","volume":"9","author":"L Zhou","year":"2019","unstructured":"Zhou L, Bhattacharjee S, Kwoh CK, et al. Trends, patient and prescriber characteristics in gabapentinoid use in a sample of United States ambulatory care visits from 2003 to 2016. J Clin Med. 2019;9(1):83.","journal-title":"J Clin Med"},{"issue":"9","key":"13397_CR20","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.14930","volume":"65","author":"LB Gerlach","year":"2017","unstructured":"Gerlach LB, Olfson M, Kales HC, Maust DT. Opioids and other central nervous system\u2013active polypharmacy in older adults in the United States. J Am Geriatr Soc. 2017;65(9):2052\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"13397_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pds.3951","volume":"25","author":"CN Kaufmann","year":"2016","unstructured":"Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993\u20132010. Pharmacoepidemiol Drug Saf. 2016;25(6):637\u201345.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"13397_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.amjmed.2018.09.026","volume":"132","author":"BA Rodwin","year":"2019","unstructured":"Rodwin BA, Salami JA, Spatz ES, et al. Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. Am J Med. 2019;132(1):61-e701. https:\/\/doi.org\/10.1016\/j.amjmed.2018.09.026.","journal-title":"Am J Med"},{"issue":"8","key":"13397_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/archinte.166.8.896","volume":"166","author":"CH Halbert","year":"2006","unstructured":"Halbert CH, Armstrong K, Gandy OH, Shaker L. Racial differences in trust in health care providers. Arch Intern Med. 2006;166(8):896\u2013901.","journal-title":"Arch Intern Med"},{"issue":"1","key":"13397_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1212\/WNL.0b013e318203e952","volume":"76","author":"DA Levine","year":"2011","unstructured":"Levine DA, Neidecker M, Kiefe CI, Karve S, Williams LS, Allison JJ. Racial\/ethnic disparities in access to physician care and medications among US stroke survivors. Neurology. 2011;76(1):53\u201361.","journal-title":"Neurology"},{"key":"13397_CR25","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1007\/s11606-013-2441-1","volume":"28","author":"EN Chapman","year":"2013","unstructured":"Chapman EN, Kaatz A, Carnes M. Physicians and implicit bias: how doctors may unwittingly perpetuate health care disparities. J Gen Intern Med. 2013;28:1504\u201310.","journal-title":"J Gen Intern Med"},{"key":"13397_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.socscimed.2017.05.009","volume":"199","author":"IW Maina","year":"2018","unstructured":"Maina IW, Belton TD, Ginzberg S, Singh A, Johnson TJ. A decade of studying implicit racial\/ethnic bias in healthcare providers using the implicit association test. Soc Sci Med. 2018;199:219\u201329.","journal-title":"Soc Sci Med"},{"issue":"9","key":"13397_CR27","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1097\/01.asn.0000026493.18542.6a","volume":"13","author":"ME Tarver-Carr","year":"2002","unstructured":"Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13(9):2363\u201370. https:\/\/doi.org\/10.1097\/01.asn.0000026493.18542.6a.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"13397_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfq473","volume":"26","author":"K Evans","year":"2011","unstructured":"Evans K, Coresh J, Bash LD, et al. Race differences in access to health care and disparities in incident chronic kidney disease in the US. Nephrol Dial Transplant. 2011;26(3):899\u2013908. https:\/\/doi.org\/10.1093\/ndt\/gfq473.","journal-title":"Nephrol Dial Transplant"},{"issue":"109","key":"13397_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15694\/mep.2019.000109.1","volume":"8","author":"U Khatri","year":"2019","unstructured":"Khatri U, Zeidan A, LaRiviere M, et al. An evaluation of implicit bias training in graduate medical education. MedEdPublish. 2019;8(109):109.","journal-title":"MedEdPublish"},{"issue":"8","key":"13397_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.22454\/FamMed.2019.947255","volume":"51","author":"M Sherman","year":"2019","unstructured":"Sherman M, Ricco J, Nelson S, Nezhad S, Prasad S. Implicit bias training in a residency program: aiming for enduring effects. Fam Med. 2019;51(8):677\u201381.","journal-title":"Fam Med"},{"issue":"1","key":"13397_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/aet2.10124","volume":"3","author":"AJ Zeidan","year":"2019","unstructured":"Zeidan AJ, Khatri UG, Aysola J, et al. Implicit bias education and emergency medicine training: step one? Awareness. AEM Educ Train. 2019;3(1):81\u20135.","journal-title":"AEM Educ Train"},{"issue":"12","key":"13397_CR32","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1097\/ACM.0000000000003559","volume":"95","author":"EG Castillo","year":"2020","unstructured":"Castillo EG, Isom J, DeBonis KL, Jordan A, Braslow JT, Rohrbaugh R. Reconsidering systems-based practice: advancing structural competency, health equity, and social responsibility in graduate medical education. Acad Med. 2020;95(12):1817\u201322.","journal-title":"Acad Med"},{"issue":"9","key":"13397_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012023","volume":"8","author":"M Alcusky","year":"2019","unstructured":"Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, Lapane KL. Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016. J Am Heart Assoc. 2019;8(9): e012023.","journal-title":"J Am Heart Assoc"},{"key":"13397_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","volume":"24","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ III, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6\u201346.","journal-title":"Neurocrit Care"},{"issue":"5","key":"13397_CR35","doi-asserted-by":"publisher","first-page":"e2110079","DOI":"10.1001\/jamanetworkopen.2021.10079","volume":"4","author":"Z Kanjee","year":"2021","unstructured":"Kanjee Z, McCann ML, Freed JA. Availability of specific direct oral anticoagulant reversal agents in US hospitals. JAMA Netw Open. 2021;4(5):e2110079-2110079.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"13397_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020697","volume":"10","author":"JA Rymer","year":"2021","unstructured":"Rymer JA, Webb L, McCall D, Hills MT, Wang TY. Differences in preferences between clinicians and patients for the use and dosing of direct oral anticoagulants for atrial fibrillation. J Am Heart Assoc. 2021;10(11): e020697.","journal-title":"J Am Heart Assoc"},{"key":"13397_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4670","author":"D Cohen","year":"2014","unstructured":"Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014. https:\/\/doi.org\/10.1136\/bmj.g4670.","journal-title":"BMJ"},{"issue":"5","key":"13397_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"K Uchino","year":"2012","unstructured":"Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397\u2013402.","journal-title":"Arch Intern Med"},{"issue":"9","key":"13397_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc1112874","volume":"366","author":"P Harper","year":"2012","unstructured":"Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864\u20136.","journal-title":"N Engl J Med"},{"issue":"9921","key":"13397_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/s0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)62343-0.","journal-title":"Lancet"},{"key":"13397_CR41","unstructured":"2012 NAMCS MICRO-DATA FILE DOCUMENTATION. https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/doc2012.pdf"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13397-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:21:08Z","timestamp":1759490468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13397-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13397"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13397-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used fully de-identified, publicly available data from the National Ambulatory Medical Care Survey (NAMCS). As secondary research with publicly available, non-identifiable information, it qualified for exemption under Category 4(ii) of the Common Rule (45 CFR 46.104 (d)). Therefore, the Institutional Review Board determined that formal review and individual informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr McManus has received research support from Bristol Myers Squibb-Pfizer, Boehringer Ingelheim, and Fitbit, and has received consulting fees from Fitbit, Heart Rhythm Society, Avania, Venturewell, and NAMSA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1300"}}